Calabrese L H, Chou S M
Cleveland Clinic Foundation, Ohio.
Rheum Dis Clin North Am. 1994 Nov;20(4):955-72.
IBM remains a poorly understood form of idiopathic inflammatory myopathy, although great progress in the areas of clinical recognition and pathophysiology have been made recently. The question of whether therapy can favorably influence short- and/or long-term outcome is still unanswered. Several recent reports suggest some possibility of at least slowing progression with immunosuppressive therapy. Long-term therapeutic trials with goals that include stabilization, rather than improvements in strength, are urgently needed.
包涵体肌炎（IBM）仍然是一种人们了解甚少的特发性炎性肌病，尽管最近在临床识别和病理生理学领域已取得了巨大进展。治疗是否能对短期和/或长期预后产生有利影响的问题仍未得到解答。最近的几份报告表明，免疫抑制治疗至少有减缓疾病进展的可能性。迫切需要开展以稳定病情而非增强肌力为目标的长期治疗试验。
